U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C28H25FN6O3
Molecular Weight 512.5349
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LY-2090314

SMILES

FC1=CC2=C3N(CCN(C2)C(=O)N4CCCCC4)C=C(C3=C1)C5=C(C(=O)NC5=O)C6=CN=C7C=CC=CN67

InChI

InChIKey=HRJWTAWVFDCTGO-UHFFFAOYSA-N
InChI=1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37)

HIDE SMILES / InChI
Molecular Formula C28H25FN6O3
Molecular Weight 512.5349
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26735141 | https://www.ncbi.nlm.nih.gov/pubmed/26403509 | https://clinicaltrials.gov/ct2/show/NCT01632306

LY-2090314 is a GSK-3alpha and GSK-3beta inhibitor developed by Eli Lilly. Phase 2 clinical trials of LY-2090314 as a signle agenst against acute leukemia did not show clinical benefit. LY-2090314 was studied in combination pemetrexed and carboplatin against solid tumors, and in combination with FOLFOX, gemcitabine, and nab-paclitaxel against pancreatic cancer.

Originator

Eli Lilly
239
Curator's Comment: # Eli Lilly

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 1.5 nM [IC50]
Inhibitor
8504
 0.9 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
603 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23305709
40 mg single, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: PEMETREXED|carboplatin
PEMETREXED|carboplatin
 LY-2090314 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1700 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23305709
120 mg single, intravenous
dose: 120 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: PEMETREXED|carboplatin
PEMETREXED|carboplatin
 LY-2090314 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
976 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23305709
40 mg single, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: PEMETREXED|carboplatin
PEMETREXED|carboplatin
 LY-2090314 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3310 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23305709
120 mg single, intravenous
dose: 120 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: PEMETREXED|carboplatin
PEMETREXED|carboplatin
 LY-2090314 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.15 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23305709
40 mg single, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: PEMETREXED|carboplatin
PEMETREXED|carboplatin
 LY-2090314 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.97 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23305709
120 mg single, intravenous
dose: 120 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: PEMETREXED|carboplatin
PEMETREXED|carboplatin
 LY-2090314 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23305709
40 mg single, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: PEMETREXED|carboplatin
PEMETREXED|carboplatin
 LY-2090314 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P00ECUN
https://www.1pchem.com/search?query=1P00ECUN
ApexBio Technology
A3570
https://www.apexbt.com/catalogsearch/result/?q=A3570
AstaTech
41538
http://astatechinc.com/CPSResult.php?CRNO=41538
BLD Pharm
BD630787
http://www.bldpharm.com/search/Search.html?keyword=BD630787
Chem Scene
CS-1633
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-1633
ChemShuttle
140520
https://www.chemshuttle.com/catalogsearch/result/?q=140520
eMolecules
252349374
https://orderbb.emolecules.com/search/#?query=252349374
eMolecules
49572923
https://orderbb.emolecules.com/search/#?query=49572923
Excenen
EX-A2214
http://www.excenen.com/searchresultlist.php?id=EX-A2214
KeyOrganics
AS-56097
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56097
mcule
MCULE-3636467091
https://mcule.com/MCULE-3636467091/
MedChem Express
HY-16294
https://www.medchemexpress.com/search.html?q=HY-16294&ft=&fa=&fp=
Molnova
M15255
https://www.molnova.com/en/serch-list.html?keywords=M15255
MolPort
MolPort-035-944-332
https://www.molport.com/shop/molecule-link/MolPort-035-944-332
MuseChem
I004274
https://www.musechem.com/product/I004274.html
Selleck Chemicals
S7063
http://www.selleckchem.com/search.html?searchDTO.searchParam=S7063
ShangHai Biochempartner
BCP000923
http://www.biochempartner.com/search_BCP000923
ShangHai Biochempartner
BCP07855
http://www.biochempartner.com/search_BCP07855
TargetMol
T1755
https://www.targetmol.com/search?keyword=T1755
Tetrahedron
TS94792
http://www.thsci.com/search.do?q=TS94792
PubMed

PubMed

TitleDatePubMed
Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.
2009-06
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.
2006-07-25
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
2004-07-29
GSK-3: tricks of the trade for a multi-tasking kinase.
2003-04-01
Patents

Patents

20100166884
1
20100261712
1
20130039996
1
20140235621
1
8318713
1
8648063
1
8802668
1
9044487
1
WO2009006043A2
1
WO2009006043A3
1
WO2010120614A1
1
WO2015066053A2
7

Sample Use Guides

In Vivo Use Guide
In clinical trial agaisnt AML 40mg LY2090314 was administered intravenously on days 1, 8 and 15 of a 28 day cycle.
Route of Administration: Intravenous
In Vitro Use Guide
Inhibition of GSK3-alpha was determined in biochemical assay. A standard filter binding protocol was used measuring the ability of recombinant GSK3-alpha to phosphorylate phospho-CREB (cAMP response element binding protein) at serine-129 with ATP[gamma-33P] in the presence of test compound.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:15:44 GMT 2025
Edited
by admin
on Mon Mar 31 18:15:44 GMT 2025
Record UNII
822M3GYM67
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LY2090314
Preferred Name English
LY-2090314
Code English
LY 2090314 [WHO-DD]
Common Name English
1H-PYRROLE-2,5-DIONE, 3-(9-FLUORO-1,2,3,4-TETRAHYDRO-2-(1-PIPERIDINYLCARBONYL)PYRROLO(3,2,1-JK)(1,4)BENZODIAZEPIN-7-YL)-4-IMIDAZO(1,2-A)PYRIDIN-3-YL-
Systematic Name English
PYRROLO(3,2,1-JK)(1,4)BENZODIAZEPINE, 7-(2,5-DIHYDRO-4-IMIDAZO(1,2-A)PYRIDIN-3-YL-2,5-DIOXO-1H-PYRROL-3-YL)-9-FLUORO-1,2,3,4-TETRAHYDRO-2-(1-PIPERIDINYLCARBONYL)-
Systematic Name English
Code System Code Type Description
NCI_THESAURUS
C116849
Created by admin on Mon Mar 31 18:15:44 GMT 2025 , Edited by admin on Mon Mar 31 18:15:44 GMT 2025
PRIMARY
EPA CompTox
DTXSID90209085
Created by admin on Mon Mar 31 18:15:44 GMT 2025 , Edited by admin on Mon Mar 31 18:15:44 GMT 2025
PRIMARY
DRUG BANK
DB11913
Created by admin on Mon Mar 31 18:15:44 GMT 2025 , Edited by admin on Mon Mar 31 18:15:44 GMT 2025
PRIMARY
SMS_ID
100000175593
Created by admin on Mon Mar 31 18:15:44 GMT 2025 , Edited by admin on Mon Mar 31 18:15:44 GMT 2025
PRIMARY
FDA UNII
822M3GYM67
Created by admin on Mon Mar 31 18:15:44 GMT 2025 , Edited by admin on Mon Mar 31 18:15:44 GMT 2025
PRIMARY
ChEMBL
CHEMBL362558
Created by admin on Mon Mar 31 18:15:44 GMT 2025 , Edited by admin on Mon Mar 31 18:15:44 GMT 2025
PRIMARY
CHEBI
167661
Created by admin on Mon Mar 31 18:15:44 GMT 2025 , Edited by admin on Mon Mar 31 18:15:44 GMT 2025
PRIMARY
PUBCHEM
10029385
Created by admin on Mon Mar 31 18:15:44 GMT 2025 , Edited by admin on Mon Mar 31 18:15:44 GMT 2025
PRIMARY
CAS
603288-22-8
Created by admin on Mon Mar 31 18:15:44 GMT 2025 , Edited by admin on Mon Mar 31 18:15:44 GMT 2025
PRIMARY
Related Record Type Details
Structure of LY-2090314 ETHANOL SOLVATE
SOLVATE->ANHYDROUS
GLYCOGEN SYNTHASE KINASE-3 BETA
INHIBITOR -> TARGET
BINDING
IC50
GLYCOGEN SYNTHASE KINASE-3 ALPHA
INHIBITOR -> TARGET
BINDING
IC50
Related Record Type Details
Structure of LY-2090314
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

Tmax PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966